2026-2035 年體外注射器市場機會、成長促進因素、產業趨勢分析及預測。

全球體外注射器市場預計到 2025 年將達到 12 億美元，並以 16.4% 的複合年成長率成長，到 2035 年達到 52 億美元。

隨著醫療服務模式不斷向更便利、以病人為中心的治療模式轉變，穿戴式給藥市場正蓬勃發展。慢性病盛行率的上升、居家照護需求的日益成長以及生物製藥的廣泛應用，進一步推動了對穿戴式給藥技術的需求。體表注射器透過在患者身上佩戴後，於指定時間內持續給藥，為皮下給藥提供了一種穿戴式方式。生物製藥的廣泛應用尤其促進了市場發展，因為這些療法通常需要可靠且可控的給藥方法。隨著治療方案日益個人化，長期治療也變得越來越普遍，醫護人員和患者都在尋求能夠提高便利性、治療順從性和給藥效率的給藥系統。穿戴式裝置、可程式設計給藥機制、連接性和裝置小型化等方面的技術進步，也為製造商創造了新的機會。此外，人們也越來越重視減少對傳統醫療機構的依賴，也加速了自我給藥技術的研發和應用。預計這些趨勢將推動體外噴射器市場持續成長至 2035 年。

預計到2025年，可可程式設計穿戴注射器市佔率將達到58.8%。隨著醫療專業人員越來越重視個人化治療和精準給藥，對這類設備的需求也不斷成長。可程式設計系統允許使用者和醫療專業人員根據治療需求設定給藥速率、給藥時間和劑量等特定參數。這種柔軟性使得該技術在涉及複雜生物製藥以及需要控制長期給藥的治療中特別實用。設備編程、自動化、給藥精度和使用者介面方面的持續改進有望提升可程式設計注射器的功能。此外，對便捷給藥和更精細化治療方案控制的需求不斷成長，預計也將整體醫療保健產業的普及應用。

到2025年，居家醫療產業將佔據46.2%的市場。隨著以患者為中心的治療模式以及在傳統臨床環境之外提供護理在醫療保健系統中日益重要，該行業正在不斷擴張。穿戴式注射器為患者提供了一種在家中接受處方治療的替代方式，同時支持治療的連續性。其穿戴式設計減少了患者因用藥而反覆前往醫療機構的次數，提高了便利性。對自我給藥的需求不斷成長、醫療保健成本不斷上漲以及對長期治療管理的需求，正促使醫療保健提供者和患者考慮更靈活的給藥方式。穿戴式注射器在設計、易用性和給藥可靠性方面的持續創新，可望進一步推動穿戴式給藥技術在居家醫療領域的應用。

預計到2025年，北美體外注射器市佔率將達到51.3%，並在2026年至2035年間以16.4%的複合年成長率成長。該地區強勁的成長主要得益於慢性病盛行率的上升以及由此帶來的長期藥物管理需求。此外，生物製藥的廣泛應用也推動了對可控劑量和便利性的先進給藥系統的需求。北美完善的醫療保健基礎設施、醫療技術的高普及率以及對居家護理日益成長的重視，為體外注射器的推廣應用創造了有利環境。預計在整個預測期內，對創新給藥平台、以患者為中心的醫療保健解決方案以及穿戴式醫療技術的持續投資將進一步增強該地區的需求。

目錄

第1章：調查方法

第2章執行摘要

第3章 行業洞察

• 產業生態系分析
• 影響產業的因素
  • 成長促進因素
    • 慢性病發生率增加
    • 過渡到居家醫療
    • 生物製藥需求不斷成長
    • 全球老化
  • 產業潛在風險與挑戰
    • 穿戴式注射器成本高昂
    • 技術和設計挑戰
  • 市場機遇
    • 人們越來越傾向於居家照護和遠端監控
• 成長潛力分析
• 監理情勢
  • 北美洲
  • 歐洲
• 技術展望
  • 最新科技趨勢
  • 新興技術
• 未來市場趨勢
• 人工智慧和生成式人工智慧對市場的影響
• 專利分析
• 價格趨勢分析
• 波特的分析
• PESTLE分析

第4章 競爭情勢

• 介紹
• 企業市佔率分析
  • 世界
  • 北美洲
  • 歐洲
• 企業矩陣分析
• 主要市場公司的競爭分析
• 競爭定位矩陣
• 主要進展
  • 併購
  • 夥伴關係和聯盟
  • 新產品發布
  • 業務拓展計劃

第5章 市場估算與預測：依設備類型分類，2022-2035年

• 可程式設計穿戴式式噴油器
• 不可程式穿戴式式噴油器

第6章 市場估計與預測：依應用領域分類，2022-2035年

• 免洗穿戴式注射器
• 可重複使用的穿戴式注射器

第7章 市場估計與預測：依技術分類，2022-2035年

• 馬達驅動
• 彈簧型
• 擴充電池
• 旋轉泵
• 其他技術

第8章 市場估算與預測：依應用領域分類，2022-2035年

• 腫瘤學
• 心血管疾病
• 自體免疫疾病
• 感染疾病
• 糖尿病
• 其他用途

第9章 市場估計與預測：依最終用途分類，2022-2035年

• 醫院
• 居家醫療
• 專科診所及門診手術中心

第10章 市場估價與預測：依地區分類，2022-2035年

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
• 世界其他地區

第11章：公司簡介

• Amgen Inc.
• Becton, Dickinson and Company（BD）
• Eitan Medical
• Enable Injections, Inc.
• Gerresheimer AG
• Insulet Corporation
• Medtronic plc
• Roche Holding AG
• scPharmaceuticals Inc.
• Sensile Medical AG
• Sorrel Medical（LTS Device Technologies）
• Stevanato Group
• Tandem Diabetes Care, Inc.
• West Pharmaceutical Services, Inc.
• Ypsomed Holding AG

The Global On-body Injector Market was valued at USD 1.2 billion in 2025 and is estimated to grow at a CAGR of 16.4% to reach USD 5.2 billion by 2035.

The market is gaining significant momentum as healthcare delivery continues to move toward convenient, patient-centered treatment models. Rising rates of chronic conditions, increasing preference for home-based care, and expanding use of biologic medicines are creating stronger demand for wearable drug delivery technologies. On-body injectors provide a wearable approach to subcutaneous drug administration by delivering medication over a defined period after the device is placed on the patient's body. The expanding use of biologics is particularly supporting market development because these therapies often require reliable and controlled delivery methods. As treatment protocols become more personalized and long-term therapies become increasingly common, healthcare providers and patients are seeking drug delivery systems that can improve convenience, treatment adherence, and administration efficiency. Technological progress in wearable devices, programmable delivery mechanisms, connectivity, and device miniaturization is also creating new opportunities for manufacturers. In addition, the growing emphasis on reducing dependence on conventional healthcare settings is encouraging the development and adoption of self-administration technologies. These trends are expected to support sustained expansion of the On-body Injector Market through 2035.

The programmable wearable injectors segment captured 58.8% share in 2025. Demand for these devices is increasing as healthcare providers place greater emphasis on individualized treatment and accurate medication delivery. Programmable systems allow users or healthcare professionals to establish specific delivery rates, administration schedules, and dosage parameters according to therapy requirements. This flexibility makes the technology particularly valuable for treatments involving complex biologic formulations or controlled medication delivery over extended periods. Continued improvements in device programming, automation, dose accuracy, and user interfaces are expected to enhance the functionality of programmable wearable injectors. Growing demand for convenient administration and greater control over treatment regimens is also likely to strengthen adoption across healthcare applications.

The homecare settings segment accounted for 46.2% share in 2025. The segment is expanding as healthcare systems increasingly emphasize patient-centric treatment models and care delivery outside traditional clinical environments. On-body injectors provide patients with an alternative method for receiving prescribed therapies while supporting treatment continuity in home-based settings. Their wearable design can improve convenience by reducing the need for repeated visits to healthcare facilities for medication administration. Growing demand for self-administration, increasing healthcare costs, and the need for long-term treatment management are encouraging providers and patients to consider more flexible drug delivery options. Continued innovation in wearable injector design, ease of use, and administration reliability is expected to further support the adoption of on-body delivery technologies in homecare settings.

North America On-body Injector Market recorded a 51.3% share in 2025 and is forecast to grow at a CAGR of 16.4% from 2026 to 2035. Strong regional growth is being supported by the increasing prevalence of chronic conditions and the resulting need for long-term medication management. Rising utilization of biologic therapies is also increasing demand for advanced drug delivery systems that can provide controlled and convenient administration. North America's established healthcare infrastructure, high adoption of medical technologies, and growing emphasis on home-based treatment are creating favorable conditions for on-body injector adoption. Continued investments in innovative drug delivery platforms, patient-focused healthcare solutions, and wearable medical technologies are expected to further strengthen regional demand throughout the forecast period.

Prominent companies operating in the global on-body injector market include Amgen Inc., Becton, Dickinson and Company (BD), Eitan Medical, Enable Injections, Inc., Gerresheimer AG, Insulet Corporation, Medtronic plc, Roche Holding AG, scPharmaceuticals Inc., Sensile Medical AG, Sorrel Medical (LTS Device Technologies), Stevanato Group, Tandem Diabetes Care, Inc., West Pharmaceutical Services, Inc., and Ypsomed Holding AG. Companies in the global on-body injector market are strengthening their market presence through product innovation, strategic partnerships, manufacturing expansion, and investments in advanced wearable drug delivery technologies. Leading participants are focusing on improving device usability, delivery accuracy, reliability, and patient convenience to support broader adoption. Companies are also developing programmable and digitally enabled injector platforms that provide greater control over medication administration. Strategic collaborations with pharmaceutical companies, healthcare providers, and technology developers are helping manufacturers accelerate device development and expand commercial opportunities. Businesses are investing in production capabilities, automation, quality systems, and scalable manufacturing processes to address increasing demand. Portfolio expansion is another important strategy, with companies developing different device configurations to accommodate varied therapeutic and administration requirements. Market participants are also strengthening regulatory capabilities and expanding geographic distribution networks to improve commercialization. Continued investments in research and development, patient-centric design, connectivity, and device miniaturization are helping companies differentiate their offerings, strengthen customer relationships, and establish a stronger foothold in the global on-body injector market.

Table of Contents

Chapter 1 Research Methodology

• 1.1 Research approach
• 1.2 Quality commitments
  • 1.2.1 GMI AI policy and data integrity commitment
    • 1.2.1.1 Source consistency protocol
• 1.3 Research trail and confidence scoring
  • 1.3.1 Research trail components
  • 1.3.2 Scoring components
• 1.4 Data collection
  • 1.4.1 Partial list of primary sources
• 1.5 Data mining sources
  • 1.5.1 Paid sources
    • 1.5.1.1 Sources, by region
• 1.6 Base estimates and calculations
  • 1.6.1 Base year calculation for any one approach
• 1.7 Forecast model
  • 1.7.1 Quantified market impact analysis
    • 1.7.1.1 Mathematical impact of growth parameters on forecast
• 1.8 Research transparency addendum
  • 1.8.1 Source attribution framework
  • 1.8.2 Quality assurance metrics
  • 1.8.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 3600 synopsis
• 2.2 Key market trends
  • 2.2.1 Device type trends
  • 2.2.2 Usage type trends
  • 2.2.3 Technology trends
  • 2.2.4 Application trends
  • 2.2.5 End use trends
  • 2.2.6 Regional trends
• 2.3 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing incidence of chronic conditions
    • 3.2.1.2 Shift towards home-based healthcare
    • 3.2.1.3 Increasing demand for biologics
    • 3.2.1.4 Global aging population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of wearable injectors
    • 3.2.2.2 Technical and design challenge
  • 3.2.3 Market opportunities
    • 3.2.3.1 Rising preference for at-home care & remote monitoring
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
• 3.5 Technology landscape (Driven by primary research)
  • 3.5.1 Current technological trends
  • 3.5.2 Emerging technologies
• 3.6 Future market trends (Driven by primary research)
• 3.7 Impact of AI and Generative AI on the market (Driven by primary research)
• 3.8 Patent analysis
• 3.9 Pricing trend analysis (Driven by primary research)
• 3.10 Porter’s analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 Global
  • 4.2.2 North America
  • 4.2.3 Europe
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers and acquisitions
  • 4.6.2 Partnerships and collaborations
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Device Type, 2022 – 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Programmable wearable injectors
• 5.3 Non-programmable wearable injectors

Chapter 6 Market Estimates and Forecast, By Usage Type, 2022 – 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Disposable wearable injectors
• 6.3 Reusable wearable injectors

Chapter 7 Market Estimates and Forecast, By Technology, 2022 – 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Motor-driven
• 7.3 Spring-based
• 7.4 Expanding battery
• 7.5 Rotary pump
• 7.6 Other technologies

Chapter 8 Market Estimates and Forecast, By Application, 2022 – 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Oncology
• 8.3 Cardiovascular disease
• 8.4 Autoimmune disease
• 8.5 Infectious disease
• 8.6 Diabetes
• 8.7 Other applications

Chapter 9 Market Estimates and Forecast, By End Use, 2022 – 2035 ($ Mn)

• 9.1 Key trends
• 9.2 Hospitals
• 9.3 Homecare settings
• 9.4 Specialty clinics & ambulatory surgery centers

Chapter 10 Market Estimates and Forecast, By Region, 2022 – 2035 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
• 10.4 Rest of World

Chapter 11 Company Profiles

• 11.1 Amgen Inc.
• 11.2 Becton, Dickinson and Company (BD)
• 11.3 Eitan Medical
• 11.4 Enable Injections, Inc.
• 11.5 Gerresheimer AG
• 11.6 Insulet Corporation
• 11.7 Medtronic plc
• 11.8 Roche Holding AG
• 11.9 scPharmaceuticals Inc.
• 11.10 Sensile Medical AG
• 11.11 Sorrel Medical (LTS Device Technologies)
• 11.12 Stevanato Group
• 11.13 Tandem Diabetes Care, Inc.
• 11.14 West Pharmaceutical Services, Inc.
• 11.15 Ypsomed Holding AG